BCR and systemic lupus erythematosus: Inhibition of the BCR-component, spleen tyrosine kinase (Syk), has shown promise in attenuating skin and renal manifestations of lupus in certain mouse models [36], although translation to human trials may be complicated by the expression of Syk on a number of cell types.